The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder

Preston S Kerr; Stephen J Freedland; Stephen B Williams

doi:10.1080/14737159.2019.1665509

The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder

Expert Rev Mol Diagn. 2020 Feb;20(2):127-129. doi: 10.1080/14737159.2019.1665509. Epub 2019 Sep 9.

Authors

Preston S Kerr¹, Stephen J Freedland^{2

3}, Stephen B Williams¹

Affiliations

¹ Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
² Center for Integrated Research on Cancer and Lifestyle, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Section of Urology, Durham VA Medical Center, Durham, USA.

PMID: 31495246
DOI: 10.1080/14737159.2019.1665509

No abstract available

Keywords: PD-1; PDL-1; Urothelial carcinoma; bladder cancer; cell free DNA; cell free RNA; circulating tumor markers; metastatic; muscle-invasive; urinary biomarkers.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor*
Circulating Tumor DNA
Humans
Molecular Diagnostic Techniques*
Neoplasm Metastasis
Neoplasm Staging
Neoplastic Cells, Circulating
Urinary Bladder Neoplasms / diagnosis*
Urinary Bladder Neoplasms / etiology*

Substances

Biomarkers, Tumor
Circulating Tumor DNA